Driven by science, serving patients
Driven by science, serving patients. Distinctive science supported by excellence in development and commercialisation are at the core of our commitment to deliver medicines that make a real difference for patients.
Our expertise spans the entire life-cycle of a medicine and we have a unique combination of discovery and development strengths in small molecules and biologics, immunotherapies and protein engineering. We work in over 100 countries, integrating our extensive therapy area knowledge with a deep understanding of the needs of our local customers, payers and regulators.
We partner with others around the world, including academia, governments, industry, scientific organisations and patient groups to access the best science and molecules, to stimulate innovation and to accelerate the delivery of new medicines that target unmet patient needs.
We work with partners to tailor deals that are structured to drive real progress in healthcare and deliver value for all parties, and which are founded on trust and transparency.
We have transformed our partnering strategy with a new therapy area-led approach which combines scientific and commercial expertise aligned to our therapy areas with business development know-how. This integrated approach enables us to add maximum value to our partnerships by ensuring that opportunities have a strategic fit with our portfolio and commercial capabilities.
Areas of interest
Across our biologics and small molecule research, we are concentrating our scientific efforts and the weight of our investment, including business development, on three core therapy areas. Alongside this, we remain active in Infection and Neuroscience with targeted investments in the best opportunities and collaborations. We are also actively seeking collaborations in Personalised Healthcare (PHC) across our core therapy areas, as well as innovative technologies to enhance our science and development processes.
Our partnering process
We work together with partners to create tailored deals that are structured to drive real progress in innovative medicines, deliver value for both parties and achieve common goals.